Cardiac Pacemakers Market Size
|Study Period||2018 - 2028|
|Market Size (2023)||USD 4.52 Billion|
|Market Size (2028)||USD 5.35 Billion|
|CAGR (2023 - 2028)||3.43 %|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cardiac Pacemakers Market Analysis
The Global Cardiac Pacemakers Market size is expected to grow from USD 4.52 billion in 2023 to USD 5.35 billion by 2028, at a CAGR of 3.43% during the forecast period (2023-2028).
The COVID-19 pandemic slowed the growth of the cardiovascular market. Due to the high rate of infection and the lack of treatment, many countries are suffering and continue to carry a heavy burden on their economies and healthcare systems. Many countries had previously shut down and stopped trading with other countries due to travel restrictions, leading to a slowdown for large companies worldwide. The American College of Surgeons and the American Society of Anesthesiologists recommended a continuous reduction in the rate of new cases of COVID-19 14 days before the resumption of special surgery. Also, according to a research article published in Case Reports in Cardiology, 2020, temporary patients undergoing pacemaker transfusion are 2.5 times more likely to acquire COVID-19 infection before the first pacemaker (PPM) injection. Therefore, research suggested that the selection of temporary cardiac care providers increased the risk of long-term associated complications and transmission of infection to healthcare workers. Therefore, the market is expected to see negative growth due to the high risk associated with heart surgery during COVID-19.
The escalation of lifestyle-related disruptions, favorable reimbursement status, increased adult populations, and technological advances are expected to boost the market studied.
According to data from the World Population Prospects: Highlights 2020, approximately 1.5 billion people worldwide will be over 65 by 2050, up from 727 million by 2020. One in four people in Europe and North America will be 65 years or older by 2050. From 143 million in 2019 to 426 million by 2050, the number of people aged 80 and over is expected to triple. Pacing treatment is usually done to treat severe arrhythmia. According to a research article titled "Pacemaker Treatment for Older Patients: Survival and Specific Predicting Limits for One-Centered Experience", published in 2019, the number of older patients receiving pacemakers is growing, and European guidelines do not consider any age limits to installing a pacemaker.
In addition, according to a World Health Organization article published in July 2021, an estimated 17.9 million people worldwide die from heart disease every year, representing 31% of deaths globally, and 85% of these deaths are mainly caused by heart disease and stroke. Therefore, the growing burden of heart disease worldwide and technological advancements in the development of novel pacemakers are expected to boost the cardiovascular market during the forecast period.
Cardiac Pacemakers Market Trends
This section covers the major market trends shaping the Cardiac Pacemakers Market according to our research experts:
Implantable Cardiac Pacemakers Segment Captures the Largest Market Share and is Expected to Grow with a Lucrative Rate
The implanted cardiac pacemakers hold taken the largest market share. They are expected to register the most profitable growth rate during the forecast period. Installed pacemakers are of three main types, namely single chamber, dual-chamber, and biventricular pacemakers.
Reduced postoperative complications can cause partial growth. Biventricular pacemakers are expected to gain momentum due to the presence of multiple tracks. These devices can be installed in multiple locations as they consist of three tracks installed in the left and right atrium and the ventricle. These biventricular pacemakers are very useful due to their many benefits in helping with conditions such as ventricular dyssynchrony.
Additionally, growing technological advances and product approvals drive the segment’s growth. For example, in July 2020, Abbott Laboratories received approval from the US Food and Drug Administration for its Gallant line, which includes an implanted cardioverter-defibrillator and a cardiac resynchronization therapy defibrillator with Bluetooth technology. Advanced features in pacemaker technology, such as remote data tracking devices, secure magnetic resonance imaging (MRI) devices, and data recording functionality, boost the segment’s growth.
Therefore, implanted cardiac pacemakers are expected to show significant growth during the prognosis and boost the market.
To understand key trends, Download Sample Report
North America Captured the Largest Market Share, and May Continue to Retain its Dominance During the Forecast Period
North America emerged as the largest regional market in terms of revenue. The high prevalence of cardiovascular disease, high obesity, and favorable revenues are key factors contributing to its huge market size.
According to the report titled "The number of older people will hit the US economy 'like a' brick '- US trade secretary", published in April 2021, about 16.5% of the US population, or 54 million, were over the age of 65 by 2020. By 2030, this number will rise to 74 million. The number of people over the age of 85 who are at risk of developing heart disease is expected to increase significantly. In addition, according to the American Heart Association’s figures published in January 2019, nearly half of the American population has some form of heart disease, including high blood pressure. The spread of heart diseases creates a need for cardiovascular equipment, monitoring, and diagnostic equipment. Therefore, there is a great need for better treatment with advanced medical devices, which may drive the studied market.
In addition, the United States has become home to many key players, such as Abbott Laboratories and Boston Scientific Corporation, which play a key role in the development, construction, and marketing of cardiac suppliers. For example, in September 2019, EBR Systems Inc. acquired the US FDA Breakthrough Device Designation for WiSE (Wireless Stimulation Endocardially) CRT System to treat heart failure. Therefore, the increasing rate of heart diseases in the United States and the introduction of new products by key players are expected to boost the market during the forecast period.
Arrhythmia affects all age groups, but the risk of developing atrial fibrillation (AF) increases with age. As per Heart Disease and Stroke Statistics 2019, the risk of long-term atrial fibrillation is estimated to be 1 in 3 white people in the United States. In addition, the use of alcohol, tobacco, sedentary lifestyles, and certain over-the-counter drugs may increase the risk of arrhythmia.
Therefore, the North American cardiovascular market is expected to witness significant growth during the forecast period due to such factors.
To understand geography trends, Download Sample Report
Cardiac Pacemakers Industry Overview
The cardiac pacemakers market is moderately competitive and consists of a few dominant players, including Abbott Laboratories (ST. Jude Medical), Medtronic PLC, Boston Scientific Corporation, Biotronik SE & Co. KG, and Lepu Medical Co. Ltd.
Cardiac Pacemakers Market Leaders
Biotronik SE & Co. KG
Boston Scientific Corporation
Lepu Medical Co . Ltd
Abbott Laboratories (ST Jude Medical)
*Disclaimer: Major Players sorted in no particular order
Cardiac Pacemakers Market News
- In June 2021, India Medtronic Private Limited launched Micra AV, a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart
- In January 2021, Boston Scientific Corporation announced its plan to acquire the remote cardiac monitoring developer, Preventice Solutions.
Cardiac Pacemakers Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Lifestyle-related Disorders
4.2.2 Rapidly Growing Geriatric Population
4.2.3 Advancements in Pacemaker Technology and Minimally Invasive Procedures
4.3 Market Restraints
4.3.1 High Costs Associated with Application and Maintenance
4.3.2 Cyber Security Risk Associated with Connected Pacemakers
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
188.8.131.52 Single Chamber
184.108.40.206 Dual Chamber
5.2 By Geography
5.2.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.2.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories (ST Jude Medical)
6.1.2 Biotronik SE & Co. KG
6.1.3 Boston Scientific Corporation
6.1.4 Lepu Medical Co. Ltd
6.1.5 Medico SpA
6.1.6 Medtronic PLC
6.1.7 Oscor Inc.
6.1.8 Osypca Medical GmbH
6.1.9 Zoll Medical Corporation
6.1.10 MicroPort Scientific Corporation
6.1.11 Cook Medical
6.1.13 Sorin Group
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cardiac Pacemakers Market Research FAQs
How big is the Global Cardiac Pacemakers Market?
The Global Cardiac Pacemakers Market size is expected to reach USD 4,518.45 million in 2023 and grow at a CAGR of 3.43% to reach USD 5,348.37 million by 2028.
What is the current Global Cardiac Pacemakers Market size?
In 2023, the Global Cardiac Pacemakers Market size is expected to reach USD 4,518.45 million.
Who are the key players in Global Cardiac Pacemakers Market?
Medtronic PLC, Biotronik SE & Co. KG, Boston Scientific Corporation, Lepu Medical Co . Ltd and Abbott Laboratories (ST Jude Medical) are the major companies operating in the Global Cardiac Pacemakers Market.
Which is the fastest growing region in Global Cardiac Pacemakers Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Global Cardiac Pacemakers Market?
In 2023, the North America accounts for the largest market share in the Global Cardiac Pacemakers Market.
Global Cardiac Pacemakers Industry Report
Statistics for the 2023 Global Cardiac Pacemakers market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Cardiac Pacemakers analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.